N-(4-氨基-3-氯苯甲酰基)-3-甲基-L-缬氨酰-N-[(2R,3S)-2-乙氧基四氢-5-氧代-3-呋喃基]-L-脯氨酰胺

VX-765是一种有效的选择性的caspase-1抑制剂， K_i为0.8 nM。Phase 2。VX-765 is an orally absorbed prodrug of VRT-043198, which exhibits potent inhibition against ICE/caspase-1 and caspase-4 with Ki of 0.8 nM and less than 0.6 nM, respectively. And VRT-043198 also inhibits IL-1β release from both PBMCs and whole blood with IC50 of 0.67 μM and 1.9 μM, respectively.In collagen-induced arthritis mouse model, VX-765 (200 mg/kg) inhibits LPS-induced IL-1β production by about 60%, and results in a dose-dependent, statistically significant reduction in the inflammation scores and effective protection from joint changes. In vivo, VX-765 blocks kindling epileptogenesis in rats by preventing IL-1β increase in forebrain astrocytes without significant effect on afterdischarge duration. In the mouse model of acute seizures, VX-765 (50 mg/kg-200 mg/kg) produces the anticonvulsant effect by delaying the time to onset of the first seizure and decreasing the number of seizures as well as their total duration by average 50% and 64%. In adult rats with genetic absence epilepsy (GAERS), VX-765, after the 3rd drug injection, significantly reduces the cumulative duration and number of spike-and-wave discharges (SWDs) by 55% on average by selectively blocking IL-1β biosynthesis.VX-765 is a potent and selective inhibitor of interleukin-converting enzyme/caspase-1.Belnacasan (VX-765)是一种有效的选择性caspase-1抑制剂，无细胞试验中Ki为0.8 nM。Phase 2。

Target	Value
Caspase-4 (Cell-free assay)	<0.6 nM(Ki)
Caspase-1 (Cell-free assay)	0.8 nM(Ki)

VX-765是一种口服可吸收的VRT-043198前药，其对ICE/caspase-1 和caspase-4表现出有效的抑制作用，Ki 分别为0.8 nM 和<0.6 nM。VRT-043198也会抑制IL-1β从PBMCs和全血中的释放，IC50分别为0.67 μM 和1.9 μM。

在胶原诱导的关节炎小鼠模型中，VX-765 (200 mg/kg)抑制60% LPS诱导的IL-1β产生，并导致炎症比例剂量依赖性显著减少，对关节病变也能够产生有效保护作用。在体内，VX-765通过防止前脑星形胶质细胞中IL-1β的增加阻断大鼠体内的癫痫发生，而对后放电持续时间没有显著影响。在急性癫痫小鼠模型中，VX-765 (50 mg/kg-200 mg/kg)通过延迟首次癫痫开始时间，并减少平均50%的癫痫发作次数以及64%的总持续时间，产生抗痉挛作用。在患有遗传性失神癫痫的成年大鼠体内，VX-765药物注射3天后，通过选择性阻断IL-1β生物合成，显著降低累积持续时间和平均55%的棘慢波放电(SWDs)。